by Third Horizon | May 2, 2025 | Life Sciences, Tea Leaves
The Food and Drug Administration (FDA) will survey 250 compounding pharmacies that produce customized versions of prescription drugs, amid ongoing concerns about safety and quality. Compounded drugs, which are not FDA-approved, have surged in popularity, especially...
by Jessica Casebolt | Jul 17, 2024 | Life Sciences, Tea Leaves
Pfizer has unveiled plans to develop an oral daily medication for weight loss, similar to existing treatments like Ozempic and Zepbound. The pharmaceutical giant reported positive results from clinical trials of its oral GLP-1 agonist candidate danuglipron, indicating...
by Jessica Casebolt | Jul 17, 2024 | Life Sciences, Tea Leaves
A recent study published in JAMA Network Open suggests that GLP-1 medications like Ozempic and Wegovy may reduce the risk of several obesity-associated cancers in individuals with type 2 diabetes. Overweight and obese individuals face heightened risks for 13 types of...
by Jessica Casebolt | Jul 16, 2024 | Life Sciences, Tea Leaves
A recent report indicates that while shortages of chemotherapy drugs like cisplatin and carboplatin have eased in the United States, concerns persist among major cancer centers regarding ongoing supply issues. According to a survey released by the National...
by Jessica Casebolt | Jul 16, 2024 | Life Sciences, Tea Leaves
Early research suggests a new slow-release ketamine pill could offer a promising option for treating hard-to-treat depression with fewer side effects compared to existing treatments. While no form of ketamine has FDA approval for psychiatric disorders, derivatives...
by Jessica Casebolt | Jul 16, 2024 | Life Sciences, Tea Leaves
Novo Nordisk has announced plans to construct a $4.1 billion factory in Clayton, North Carolina, aimed at addressing shortages of its popular weight-loss and diabetes drugs, Wegovy and Ozempic. This move comes amidst widespread patient difficulties in accessing GLP-1...
Recent Comments